Tejas Savant
Stock Analyst at Morgan Stanley
(3.20)
# 1,171
Out of 5,090 analysts
250
Total ratings
48.94%
Success rate
0.44%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $40 → $48 | $44.61 | +7.60% | 15 | Dec 2, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $572.77 | +16.98% | 16 | Dec 2, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $80 → $85 | $76.66 | +10.88% | 6 | Dec 2, 2025 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $24 | $22.11 | +8.55% | 3 | Dec 2, 2025 | |
| PSNL Personalis | Maintains: Equal-Weight | $9 → $11 | $9.56 | +15.06% | 14 | Dec 2, 2025 | |
| NTRA Natera | Maintains: Overweight | $220 → $265 | $244.55 | +8.36% | 15 | Dec 2, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $250 → $265 | $225.85 | +17.33% | 12 | Dec 2, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $85 → $110 | $100.98 | +8.93% | 3 | Dec 2, 2025 | |
| TXG 10x Genomics | Downgrades: Equal-Weight | $17 → $20 | $17.77 | +12.55% | 16 | Dec 2, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $69 → $76 | $74.97 | +1.37% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $16 | $14.75 | +8.47% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $128.96 | -18.58% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $10.93 | +9.79% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $11.90 | -32.77% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $7 | $4.99 | +40.28% | 9 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $9.54 | -26.62% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.70 | +35.14% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $7.09 | +196.19% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $2.39 | -16.32% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $9.25 | +332.43% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.03 | +196.30% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.85 | +106.19% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.98 | -30.90% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.88 | +431.91% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $102.02 | -28.45% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $184.31 | +35.64% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $7.68 | +1,202.93% | 5 | May 12, 2022 |
Veracyte
Dec 2, 2025
Maintains: Underweight
Price Target: $40 → $48
Current: $44.61
Upside: +7.60%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $572.77
Upside: +16.98%
Tempus AI
Dec 2, 2025
Maintains: Overweight
Price Target: $80 → $85
Current: $76.66
Upside: +10.88%
Stevanato Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $24
Current: $22.11
Upside: +8.55%
Personalis
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $11
Current: $9.56
Upside: +15.06%
Natera
Dec 2, 2025
Maintains: Overweight
Price Target: $220 → $265
Current: $244.55
Upside: +8.36%
IQVIA Holdings
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $225.85
Upside: +17.33%
GRAIL
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $85 → $110
Current: $100.98
Upside: +8.93%
10x Genomics
Dec 2, 2025
Downgrades: Equal-Weight
Price Target: $17 → $20
Current: $17.77
Upside: +12.55%
Hologic
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $69 → $76
Current: $74.97
Upside: +1.37%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $11 → $16
Current: $14.75
Upside: +8.47%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $128.96
Upside: -18.58%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $10.93
Upside: +9.79%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $11.90
Upside: -32.77%
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $4.99
Upside: +40.28%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $9.54
Upside: -26.62%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.70
Upside: +35.14%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $7.09
Upside: +196.19%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $2.39
Upside: -16.32%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $9.25
Upside: +332.43%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.03
Upside: +196.30%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.85
Upside: +106.19%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.98
Upside: -30.90%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.88
Upside: +431.91%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $102.02
Upside: -28.45%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $184.31
Upside: +35.64%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $7.68
Upside: +1,202.93%